what is glp 1 agonist drugs GLP-1 Receptor Agonists and Other GLP-1R Agonists for Weight Loss

As this medication is newer, we continue to closely monitor the research and patient outcomes

These factors are creating a strong foundation for mainstream adoption This shift toward multi-indication GLP-1 therapies is redefining treatment protocols and broadening healthcare strategies aimed at chronic disease management

Description of exendin-3(9-39) amide, a specific exendin receptor antagonist

A randomised controlled trial was conducted in 2022 investigating the impact of semaglutide and liraglutide on weight loss in individuals living with obesity

Insulin remains the preferred choice only when GLP-1 drugs are contraindicated, unaffordable, or insufficient alone, or when the patient has Type 1 diabetes

Numerous other trials have demonstrated positive cardiovascular outcomes with focus on HFpEF in the SUMMIT trial for tirzepatide and the STEP-HFpEF trial for semaglutide [50,51,52]